Little Green Pharma (ASX:LGP) secures WA psilocybin licence
Little Green Pharma (ASX:LGP) secures Western Australian psilocybin license
Global leaders join forces down under
$40m psychedelic medicine institute launches in Melbourne
Researchers from leading universities around the globe are joining forces to make psychedelic medicine a reality.
This Friday, a $40 million psychedelic research institute called The Psychae Institute will launch in Melbourne, Australia. The institute will study psilocybin, MDMA, and DMT to develop pharmaceutical-grade psychedelic medicines, and will oversee clinical studies in the UK, Canada, Europe, and Brazil. A co-director of the institute explains that Australia is the ideal location because clinical trials do not need sign-off from an ethics committee, unlike many countries.
Snorting shrooms?
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
PsiloThera isn’t the only company changing the way we take drugs.
atai Life Sciences (ATAI) is partnering with the University of Queensland to commercialize a new nose-to-brain drug delivery technology for psychedelic and non-psychedelic compounds. The nasal method has potential to be more effective at treating central nervous system (CNS) disorders than oral administration because it bypasses the blood-brain barrier that can restrict the entry of therapeutic agents. The nose-to-brain technology may require a lower dose than oral methods and may reduce dosing frequency too – plus its non-invasive and painless.
Is microdosing a placebo? An Australian study will find out
Psychedelic microdosing study to reveal what really happens in brains
Microdosers report enhanced cognitive performance and improved mental health, but is it all just a placebo? A new study in Sydney, Australia will reveal the answer.
Macquarie University is recruiting 80 candidates for a placebo-controlled study that will use brain scans and biomarkers to see if the benefits of microdosing psilocybin can be measured on a physiological level. We’ll cover the findings in a future issue, so stay tuned 😉
Get motivated with microdosing
Microdoses of psilocybin and ketamine enhance motivation and attention in rodent models relevant to depression
If you want to be more productive, a morning microdose might be just what you need. A recent study found that low doses of psilocybin increased task motivation, attentional accuracy, and impulsive action in low-performing rats based on repeated behavioural tests. The findings suggest that microdosing may have potential to treat major depressive disorder.